European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results from the treatment of mucosal cancers

Christina Caroline Plaschke, Giulia Bertino, James A. McCaul, Juan J. Grau, Remco de Bree, Gregor Sersa, Antonio Occhini, Ales Groselj, Cristobal Langdon, Derrek A. Heuveling, Maja Cemazar, Primoz Strojan, C. Rene Leemans, Marco Benazzo, Francesca De Terlizzi, Irene Wessel, Julie Gehl

Research output: Contribution to journalArticle

Abstract

Aim Electrochemotherapy is an effective local treatment for cutaneous tumours and metastases. In this prospective trial, six European institutions investigated electrochemotherapy in recurrent, mucosal head and neck tumours. Patient and methods Forty-three patients with recurrent mucosal head and neck tumours and no further curative or reasonably effective palliative treatment options were enrolled and treated with electrochemotherapy. Patients were treated in general anaesthesia using intravenous or local injection of bleomycin followed by delivery of electric pulses to the tumour area. Primary end-point was local tumour response. Secondary end-points were safety and toxicity, overall and progression free survival, and quality-of-life. Results Thirty-seven patients were evaluable for tumour response, pain score, side-effects and quality of life questionnaires. Six patients were not evaluable due to lost follow-up, disease progression or death before evaluation. Intention to treat analysis revealed an objective response of 56% (complete response 8 (19%), partial response 16 (37%), stable disease 10 (23%), progressive disease 3 (7%), and not evaluable 6 (14%)). Three patients (7%) remained in complete response at 30, 34, and 84 months post-treatment. The treatment procedure was generally well tolerated. Swelling of the mucosa was observed in the first days after treatment. Pain and use of pain medication rose temporarily; fatigue and dysphagia were also noted in the quality of life assessment. Conclusion Electrochemotherapy can be applied to mucosal head and neck recurrent tumours accessible to the procedure with promising objective response, survival and toxicity profile. Attention should be paid to post-treatment swelling and planning of pain medication. These favourable results indicate that electrochemotherapy could play a role in patients with recurrent head and neck cancer.

Original languageEnglish
Pages (from-to)172-181
Number of pages10
JournalEuropean Journal of Cancer
Volume87
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

Electrochemotherapy
Head and Neck Neoplasms
Research
Neoplasms
Pain
Neck
Head
Quality of Life
Therapeutics
Intention to Treat Analysis
Lost to Follow-Up
Bleomycin
Deglutition Disorders
Palliative Care
General Anesthesia
Disease-Free Survival
Fatigue
Disease Progression
Mucous Membrane
Neoplasm Metastasis

Keywords

  • Electrochemotherapy
  • Head and neck cancer
  • Palliative treatment
  • Quality of life
  • Squamous cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project : Results from the treatment of mucosal cancers. / Plaschke, Christina Caroline; Bertino, Giulia; McCaul, James A.; Grau, Juan J.; de Bree, Remco; Sersa, Gregor; Occhini, Antonio; Groselj, Ales; Langdon, Cristobal; Heuveling, Derrek A.; Cemazar, Maja; Strojan, Primoz; Leemans, C. Rene; Benazzo, Marco; De Terlizzi, Francesca; Wessel, Irene; Gehl, Julie.

In: European Journal of Cancer, Vol. 87, 01.12.2017, p. 172-181.

Research output: Contribution to journalArticle

Plaschke, CC, Bertino, G, McCaul, JA, Grau, JJ, de Bree, R, Sersa, G, Occhini, A, Groselj, A, Langdon, C, Heuveling, DA, Cemazar, M, Strojan, P, Leemans, CR, Benazzo, M, De Terlizzi, F, Wessel, I & Gehl, J 2017, 'European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results from the treatment of mucosal cancers', European Journal of Cancer, vol. 87, pp. 172-181. https://doi.org/10.1016/j.ejca.2017.10.008
Plaschke, Christina Caroline ; Bertino, Giulia ; McCaul, James A. ; Grau, Juan J. ; de Bree, Remco ; Sersa, Gregor ; Occhini, Antonio ; Groselj, Ales ; Langdon, Cristobal ; Heuveling, Derrek A. ; Cemazar, Maja ; Strojan, Primoz ; Leemans, C. Rene ; Benazzo, Marco ; De Terlizzi, Francesca ; Wessel, Irene ; Gehl, Julie. / European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project : Results from the treatment of mucosal cancers. In: European Journal of Cancer. 2017 ; Vol. 87. pp. 172-181.
@article{8500bc7b1cf34d67b3c82d2e3d42a737,
title = "European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results from the treatment of mucosal cancers",
abstract = "Aim Electrochemotherapy is an effective local treatment for cutaneous tumours and metastases. In this prospective trial, six European institutions investigated electrochemotherapy in recurrent, mucosal head and neck tumours. Patient and methods Forty-three patients with recurrent mucosal head and neck tumours and no further curative or reasonably effective palliative treatment options were enrolled and treated with electrochemotherapy. Patients were treated in general anaesthesia using intravenous or local injection of bleomycin followed by delivery of electric pulses to the tumour area. Primary end-point was local tumour response. Secondary end-points were safety and toxicity, overall and progression free survival, and quality-of-life. Results Thirty-seven patients were evaluable for tumour response, pain score, side-effects and quality of life questionnaires. Six patients were not evaluable due to lost follow-up, disease progression or death before evaluation. Intention to treat analysis revealed an objective response of 56{\%} (complete response 8 (19{\%}), partial response 16 (37{\%}), stable disease 10 (23{\%}), progressive disease 3 (7{\%}), and not evaluable 6 (14{\%})). Three patients (7{\%}) remained in complete response at 30, 34, and 84 months post-treatment. The treatment procedure was generally well tolerated. Swelling of the mucosa was observed in the first days after treatment. Pain and use of pain medication rose temporarily; fatigue and dysphagia were also noted in the quality of life assessment. Conclusion Electrochemotherapy can be applied to mucosal head and neck recurrent tumours accessible to the procedure with promising objective response, survival and toxicity profile. Attention should be paid to post-treatment swelling and planning of pain medication. These favourable results indicate that electrochemotherapy could play a role in patients with recurrent head and neck cancer.",
keywords = "Electrochemotherapy, Head and neck cancer, Palliative treatment, Quality of life, Squamous cell carcinoma",
author = "Plaschke, {Christina Caroline} and Giulia Bertino and McCaul, {James A.} and Grau, {Juan J.} and {de Bree}, Remco and Gregor Sersa and Antonio Occhini and Ales Groselj and Cristobal Langdon and Heuveling, {Derrek A.} and Maja Cemazar and Primoz Strojan and Leemans, {C. Rene} and Marco Benazzo and {De Terlizzi}, Francesca and Irene Wessel and Julie Gehl",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/j.ejca.2017.10.008",
language = "English",
volume = "87",
pages = "172--181",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project

T2 - Results from the treatment of mucosal cancers

AU - Plaschke, Christina Caroline

AU - Bertino, Giulia

AU - McCaul, James A.

AU - Grau, Juan J.

AU - de Bree, Remco

AU - Sersa, Gregor

AU - Occhini, Antonio

AU - Groselj, Ales

AU - Langdon, Cristobal

AU - Heuveling, Derrek A.

AU - Cemazar, Maja

AU - Strojan, Primoz

AU - Leemans, C. Rene

AU - Benazzo, Marco

AU - De Terlizzi, Francesca

AU - Wessel, Irene

AU - Gehl, Julie

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Aim Electrochemotherapy is an effective local treatment for cutaneous tumours and metastases. In this prospective trial, six European institutions investigated electrochemotherapy in recurrent, mucosal head and neck tumours. Patient and methods Forty-three patients with recurrent mucosal head and neck tumours and no further curative or reasonably effective palliative treatment options were enrolled and treated with electrochemotherapy. Patients were treated in general anaesthesia using intravenous or local injection of bleomycin followed by delivery of electric pulses to the tumour area. Primary end-point was local tumour response. Secondary end-points were safety and toxicity, overall and progression free survival, and quality-of-life. Results Thirty-seven patients were evaluable for tumour response, pain score, side-effects and quality of life questionnaires. Six patients were not evaluable due to lost follow-up, disease progression or death before evaluation. Intention to treat analysis revealed an objective response of 56% (complete response 8 (19%), partial response 16 (37%), stable disease 10 (23%), progressive disease 3 (7%), and not evaluable 6 (14%)). Three patients (7%) remained in complete response at 30, 34, and 84 months post-treatment. The treatment procedure was generally well tolerated. Swelling of the mucosa was observed in the first days after treatment. Pain and use of pain medication rose temporarily; fatigue and dysphagia were also noted in the quality of life assessment. Conclusion Electrochemotherapy can be applied to mucosal head and neck recurrent tumours accessible to the procedure with promising objective response, survival and toxicity profile. Attention should be paid to post-treatment swelling and planning of pain medication. These favourable results indicate that electrochemotherapy could play a role in patients with recurrent head and neck cancer.

AB - Aim Electrochemotherapy is an effective local treatment for cutaneous tumours and metastases. In this prospective trial, six European institutions investigated electrochemotherapy in recurrent, mucosal head and neck tumours. Patient and methods Forty-three patients with recurrent mucosal head and neck tumours and no further curative or reasonably effective palliative treatment options were enrolled and treated with electrochemotherapy. Patients were treated in general anaesthesia using intravenous or local injection of bleomycin followed by delivery of electric pulses to the tumour area. Primary end-point was local tumour response. Secondary end-points were safety and toxicity, overall and progression free survival, and quality-of-life. Results Thirty-seven patients were evaluable for tumour response, pain score, side-effects and quality of life questionnaires. Six patients were not evaluable due to lost follow-up, disease progression or death before evaluation. Intention to treat analysis revealed an objective response of 56% (complete response 8 (19%), partial response 16 (37%), stable disease 10 (23%), progressive disease 3 (7%), and not evaluable 6 (14%)). Three patients (7%) remained in complete response at 30, 34, and 84 months post-treatment. The treatment procedure was generally well tolerated. Swelling of the mucosa was observed in the first days after treatment. Pain and use of pain medication rose temporarily; fatigue and dysphagia were also noted in the quality of life assessment. Conclusion Electrochemotherapy can be applied to mucosal head and neck recurrent tumours accessible to the procedure with promising objective response, survival and toxicity profile. Attention should be paid to post-treatment swelling and planning of pain medication. These favourable results indicate that electrochemotherapy could play a role in patients with recurrent head and neck cancer.

KW - Electrochemotherapy

KW - Head and neck cancer

KW - Palliative treatment

KW - Quality of life

KW - Squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85034068490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034068490&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2017.10.008

DO - 10.1016/j.ejca.2017.10.008

M3 - Article

C2 - 29156298

AN - SCOPUS:85034068490

VL - 87

SP - 172

EP - 181

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -